ALK reports strong growth in Q2 with revenue up 21% and operating profit up 189%.

From GlobeNewswire: 2024-08-22 11:49:00

In Q2, ALK reports a 21% growth in organic revenue and an operating profit margin of 19%. Revenue increase driven by strong tablet sales and improved performance of allergy products. European and International markets key to growth. Operating profit increased by 189%. Full-year outlook upgraded with revenue expected to grow by 14-16%.

ALK launches new strategy ‘Allergy+’ with long-term financial ambitions for 2028. Regulatory processes ongoing for allergy tablets for children in Europe and North America. Optimisation activities support growth investments and 2025 earnings goals. Full-year outlook upgraded to reflect current performance with revenue expected to grow by 14-16%.

CEO Peter Halling praises Q2 results, citing robust tablet growth and cost optimization initiatives. New strategy ‘Allergy+’ implementation well underway. Full-year financial outlook upgraded with revenue expected to grow by 14-16% and EBIT margin to improve to 19-21%. ALK hosting conference call on August 23 for analysts and investors.



Read more at GlobeNewswire:: Six-month interim report (Q2) 2024